- The Engagement Report 2016 is online
The Engagement Report 2016 is online
Friday 19 May 2017
For the fourth consecutive year, Amundi publishes its Engagement Report.
Reflecting the continuous dialogue between Amundi and the companies, this Report is based on three main axes:
- Engagementt for influence,
- Data collection for rating purposes,
- and shareholder engagement.
Amundi's engagement policy aims to support companies in taking into account environmental, social and governance (ESG) issues on specific themes, which are often controversial or subjected to a strong legislative momentum.
Two new themes were studied in 2016:
- coal use in the electricity generation sector,
- child labor in the cocoa and tobacco industry.
The report also contains detailed follow-up on the themes initiated over the past four years, in the areas of human rights, food waste, and conflict minerals. In total, out of 66 companies met, 51 agreed to be cited, proof of the importance they place on improving their practices and our engagement process.
The report also details Amundi's normative and sectoral exclusion policy, and presents the shareholder initiatives and coalitions of shareholders that we support.
Another pillar of our policy is shareholder engagement, which groups the pre-AGM (Annual General Meeting) dialogue and the exercise of voting rights at the general meetings of the companies in which the funds are invested.
In 2016, Amundi participated in more than 2,600 Assemblies, of which 76% voted with at least one opposition vote, and engaged with 240 issuers, resulting in substantial improvements in corporate practices in nearly fifty cases.
Discover the 2016 Engagement Report
Lessons learned from the Q1 2017 earnings season
As the earnings season comes to a close, the time has come to report back on what we have found.
Biosimilars – Now a reality even for complex biologics
Within the next five years, Biosimilars should take an increasingly important role as a powerful force driving down the cost of healthcare in the US and elsewhere or enabling more patients to gain access to some of the most complex biologics: eight therapies among the world’s Top 10 could face biosimilar competition, mostly in the field of inflammation.
This section develops our central scenario and our main convictions. It highlights the main orientations of our asset allocation and presents the strategies that characterize the structure of our portfolios:bond portfolios, equity portfolios and diversified portfolios.